{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:15:37Z","timestamp":1788218137888,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet to be proved.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The systematic review and meta-analysis was performed pursuant to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline and registered on PROSPERO (CRD42022303007).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Fourteen prospective studies (5 RCTs and 9 non-RCTs), enrolling a total of 1845 patients with AA, were included for quantitative analysis. In RCTs, oral JAK inhibitors resulted in higher good response rate compared with control (RR: 6.86, 95% CI: 2.91\u201316.16); topical JAK inhibitors did not show any difference compared with control (RR: 1.00, 95% CI: 0.31\u20133.18). In non-RCTs, the pooled rate of good response to oral, topical and sublingual JAK inhibitors were 63% (95% CI: 44%\u201380%), 28% (95% CI: 1%\u201372%) and 11% (95% CI: 1%\u201329%), respectively. The pooled recurrence rate in patients treated with JAK inhibitors was 54% (95% CI: 39%\u201369%), mainly due to the withdrawal of JAK inhibitors. In RCTs, no difference was found in the risk of experiencing most kind of adverse events; in non-RCTs, the reported adverse events with high incidence rate were mostly mild and manageable.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> JAK inhibitors are efficacious and generally well-tolerated in treating AA with oral administration, whereas topical or sublingual administration lacks efficacy. Subgroup analyses indicate that baricitinib, ritlecitinib and brepocitinib seem to have equal efficacy for AA in RCTs; ruxolitinib (vs. tofacitinib) and AA (vs. AT\/AU) are associated with better efficacy outcomes in non-RCT. Due to the high recurrence rate after withdrawal of JAK inhibitors, continuous treatment should be considered to maintain efficacy.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> PROSPERO: CRD 42022303007<\/jats:p>","DOI":"10.3389\/fphar.2022.950450","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T10:16:23Z","timestamp":1661336183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies"],"prefix":"10.3389","volume":"13","author":[{"given":"Diqin","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","volume-title":"Cochrane Handbook for systematic Reviews of interventions","author":"Akl","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/ijd.15917","article-title":"Alopecia areata and tofacitinib: A prospective multicenter study from a Saudi population","volume":"61","author":"AlMarzoug","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"B3","volume-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: An open-label comparative study","author":"Almutairi","year":"2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"142205","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.116.239723","article-title":"Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor","volume":"361","author":"Elwood","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: A systemic review and meta-analysis","volume":"34","author":"Guo","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type Alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI insight"},{"key":"B12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"","journal-title":"J. Am. Acad. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"B18","DOI":"10.1016\/j.jid.2021.07.049","article-title":"LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)","volume":"141","author":"King","year":"","journal-title":"J. Investigative Dermatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"AB155","DOI":"10.1016\/j.jaad.2021.06.634","article-title":"27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial","volume":"85","author":"Ko","year":"2021","journal-title":"J. Am. Acad. Dermatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/ijd.15657","article-title":"Sublingual tofacitinib for alopecia areata: A roll-over pilot clinical trial and analysis of pharmacokinetics","volume":"60","author":"Lai","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ajd.12913","article-title":"Systemic treatments for alopecia areata: A systematic review","volume":"60","author":"Lai","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamadermatol.2018.2312","article-title":"Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: A systematic review and meta-analysis","volume":"154","author":"Lee","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"403403","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI insight"},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"B25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s0092-8674(00)81168-x","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: Targeting the JAK\/STAT pathway","volume":"3","author":"O'Shea","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","article-title":"Maintenance, withdrawal and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial","volume":"87","author":"Peeva","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: A systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: A systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4065\/70.7.628","article-title":"Incidence of alopecia areata in olmsted county, Minnesota, 1975 through 1989","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin. Proc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"AB85","DOI":"10.1016\/j.jaad.2021.06.365","article-title":"26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2\/3 BRAVE-AA1 study","volume":"85","author":"Senna","year":"2021","journal-title":"J. Am. Acad. Dermatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: A long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.950450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T10:16:28Z","timestamp":1661336188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.950450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":41,"alternative-id":["10.3389\/fphar.2022.950450"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.950450","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"950450"}}